Geraniol ameliorates the motor behavior and neurotrophic factors inadequacy in MPTP-induced mice model of parkinson's disease

Journal of Molecular Neuroscience

Volumn 51, Issue 3, 2013, Pages 851-862

  Rekha, Karamkolly R ^a   Selvakumar, Govindasamy P ^a   Sethupathy, Subramaniam ^a   Santha, Karunanidhi ^a   Sivakamasundari, Ramu Inmozhi ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

Neurodegeneration; Neuroprotective; Neurotrophic factors; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINE; GERANIOL; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE; MALONALDEHYDE; MESSENGER RNA; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BIOCHEMICAL COMPOSITION; CONTROLLED STUDY; DENERVATION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIPID PEROXIDATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ROTAROD TEST; STRIATE CORTEX; WESTERN BLOTTING;

MUS;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DOPAMINERGIC NEURONS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; LIPID PEROXIDATION; LOCOMOTION; MICE; MICE, INBRED C57BL; MPTP POISONING; NEUROPROTECTIVE AGENTS; RNA, MESSENGER; TERPENES;

EID: 84885956424     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-013-0074-9     Document Type: Article

References (67)

1. Abercrombie M (1946) Estimation of nuclear population from microtome sections. Anat Rec 94:239-247
2. Afonso-Oramas D, Cruz-Muros I, Barroso-Chinea P, Alvarez de la Rosa D, CastroHernandez J, Salas-Hernandez J, Giraldez T, Gonzalez-Hernandez T (2010) The dopamine transporter is differentially regulated after dopaminergic lesion. Neurobiol Dis 40:518-530
3. Alam ZI, Daniel SE, Lees AJ, Marsden DC (1997) A generalized increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69:1326-1329
4. Anand P (2004) Neurotrophic factors and their receptors in human sensory neuropathies. Prog Brain Res 146:477-492
5. Bespalov MM, Saarma M (2007) GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci 28:68-74
6. Bezard E, Dovero S, Belin D (2003) Enriched environment confers resistance to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors. J Neurosci 23:10999-11007
7. Boger HA, Middaugh LD, Huang P, Zaman V, Smith AC, Hoffer BJ, Tomac AC (2006) A partial GDNF depletion leads to earlier age related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Exp Neurol 202:336-347
8. Boger HA, Middaugh LD, Patrick KS (2007) Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice. J Neurosci 27:8816-8825
9. Caudle WM, Colebrooke RE, Emson PC, Mille GW (2008) Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci 31:303-308
10. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW (2009) Nrf2 mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc Natl Acad Sci 106:2933-2938
11. Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY, Bok E, Jin M, Park ES, Yoon SH, Ko HW, Kim YS, Jin BK (2011) Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 60:963-974
12. Collier TJ, Kanaan NM, Kordower JH (2011) Aging as a primary risk factor for Parkinson's disease: evidence from studies of nonhuman primates. Nat Rev Neurosci 12:359-366
13. Date I, Aoi M, Tomita S, Collins F, Ohmoto T (1998) GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged Parkinsonian mice. NeuroReport 9:2365-2369
14. Dowd E, Monville C, Torres EM, Wong LF, Azzouz M, Mazarakis ND, Dunnett SB (2005) Lentivector mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. Eur J Neurosci 22:2587-2595
15. Eberhardt O, Schulz JB (2003) Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicol Lett 139:135-151
16. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci 93:5166-5171
17. Escames G, Guerrero JM, Reiter RJ, Garcia JJ, MunozHoyos A, Ortiz GG (1997) Melatonin and vitamin E limit nitric oxide induced lipid peroxidation in rat brain homogenates. Neurosci Lett 230:147-150
18. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde, and related aldehydes. Free Radic Biol Med 11:81-128
19. Ferraro TN, Golden GT, DeMattei M, Hare TA, Fariello RG (1986) Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse. Neuropharmacology 25:1071-1074
20. Filipov NM, Norwood AB, Sistrunk SC (2009) Strain-specific sensitivity to MPTP of C57BL/6 and BALB/c mice is age dependent. Neuroreport 20:713-717
21. Hartmann A, Troadec J, Hunot S, Kikly K, Baptiste A (2001) Caspase-8 Is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci 21:2247-2255
22. Hirsch EC (2007) Animal models in neurodegenerative diseases. J Neural TransmSuppl 87-90
23. Hong M, Mukhida K, Mendez I (2008) GDNF therapy for Parkinson's disease. Expert Rev Neurother 8:1125-1139
24. Jenner P, Olanow CW (1998) Understanding cell death in Parkinson's disease. Ann Neurol 44:72-84
25. Jollow D, Mitchell L, Zampaglione N, Gillete J (1974) Bromobenzene induced liver necrosis: protective role of glutathione and evidence for 3, 4-bromobenzenoxide as the hepatotoxic intermediate. Pharmacology 11:151-169
26. Khan MM, Hoda MN, Ishrat T, Ahmad A, Khan MB, Khuwaja G, Raza SS, Safhi MM, Islam F (2010) Amelioration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced behavioral dysfunction and oxidative stress by Pycnogenol in mouse model of Parkinson's disease. Behav Pharmacol 21:563-571
27. Kingston PA, Zufall F, Barnstable CJ (1996) Rat hippocampal neurons express genes for both rod retinal and olfactory cyclic nucleotide gated channels: novel targets for cAMP/cGMP function. Proc Natl Acad Sci 93:10440-10445
28. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767-773
29. Kurosaki R, Muramatsu Y, Watanabe H, Michimata M, Matsubara M, Imai Y, Araki T (2003) Role of dopamine transporter against MPTP (1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine) neurotoxicity in mice. Metab Brain Dis 18:139-146
30. Lapchak PA, Araujo DM, Hilt DC, Jiao S, Collin F, Miyoshi Y, Yi A, Zhang Z, Gash DM (1998) Topographical distribution of [125I]-glial cell line derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection. Brain Res 789:9-22
31. Lau YS, Novikova L, Roels C (2005) MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact. Neurosci Res 52:371-378
32. Lin AM, Yang CH, Ueng YF, Luh TY, Liu TY, Lay YP, Ho LT (2004) Differential effects of carboxyfullerene on MPP+/MPTP-induced neurotoxicity. Neurochem Int 44:99-105
33. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line derived neurotrophic factor for midbrain. Science 260:1130-1132
34. Lindsay RM, Wiegand SJ, Altar CA, DiStefano PS (1994) Neurotrophic factors: from molecule to man. Trends Neurosci 17:182-190
35. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
36. Madankumar A, Jayakumar S, Gokuladhas K, Rajan B, Raghunandhakumar S, Asokkumar S, Devaki T (2013) Geraniol modulates tongue and hepatic phase I and phase II conjugation activities and may contribute directly to the chemopreventive activity against experimental oral carcinogenesis. Eur J Pharmacol 705:148-155
37. Meister A, Anderson ME (1983) Glutathione. Annu Rev Biochem 52:711-760
38. Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T (1999) Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett 270:45-48
39. Moon M, Kim HG, Hwang L, Seo JH, Kim S, Hwang S, Kim S, Lee D, Chung H, Oh MS, Lee KT, Park S (2009) Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation. Neurotox Res 15:332-347
40. Muralikrishnan D, Mohanakumar KP (1998) Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 12:905-912
41. Nicholas AP (2007) Levodopa induced hyperactivity in mice treated with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Mov Disord 22:99-104
42. Peterson AL, Nutt JG (2008) Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 5:270-280
43. Przedborski S, Tieu K, Perier C, Vila M (2004) MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 36:375-379
44. Reed DJ, Savage MK (1995) Influence of metabolic inhibitors on mitochondrial permeability transition and glutathione status. Biochim Biophys Acta 1271:43-50
45. Rozas G, Lopez-Martin E, Guerra MJ, Labandeira-Garcia JL (1998) The overall rod performance test in the MPTP-treated mouse model of Parkinsonism. J Neurosci Methods 83:165-175
46. Saarma M (2000) GDNF - a stranger in the TGF-beta superfamily? Eur J Biochem 267:6968-6971
47. Sayre LM, Smith MA, Perry G (2001) Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 8:721-738
48. Schober A (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318:215-224
49. Schwarting RK, Bonatz AE, Carey RJ, Huston JP (1991) Relationships between indices of behavioral asymmetries and neurochemical changes following mesencephalic 6-hydroxydopamine injections. Brain Res 554:46-55
50. Schwarting RK, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery, and treatments. Prog Neurobiol 50:275-331
51. Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 134:57-66
52. Stephenson DT, Childs MA, Li Q, Carvajal-Gonzalez S, Opsahl A (2007) Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys. Cell Transplant 16:229-244
53. Sundstrom E, Fredriksson A, Archer T (1990) Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. Brain Res 528:181-188
54. ansey MG, McCoy MK, Frank-Cannon TC (2007) Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208:1-25
55. Tillerson JL, Caudle WM, Reveron ME, Miller GW (2002) Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp Neurol 178:80-90
56. Tiwari M, Kakkar P (2009) Plant-derived antioxidants geraniol and camphene protect rat alveolar macrophages against t-BHP-induced oxidative stress. Toxicol In Vitro 23:295-301
57. Tsai S, Chao C, Yin M (2011) Preventive and therapeutic effects of caffeic acid against inflammatory injury in striatum of MPTP-treated mice. Eur J Pharmacol 670:441-447
58. Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O, Morari M (2008) Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced Parkinsonism. Neurobiol Dis 30:430-438
59. Wang L, Muramatsu S, Lu Y, Ikeguchi K, Fujimoto K, Okada T, Mizukami H, Hanazono Y, Kume A, Urano F, Ichinose H, Nagatsu T, Nakano I, Ozawa K (2002) Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther 9:381-389
60. Weihe E, Eiden LE (2000) Chemical neuroanatomy of the vesicular amine transporters. FASEB J 14:2435-2449
61. Wright AM, Bempong J, Kirby ML, Barlow RL, Bloomquist JR (1998) Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res 788:215-222
62. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S (2002) Blockade of microglial activation is neuroprotective in the1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's Disease. J Neurosci 22:1763-1771
63. Wu SS, Frucht SJ (2005) Treatment of Parkinson's disease - what's on the horizon? CNS Drugs 19:723-743
64. Xu G, Xiongy Z, Yong Y, Wang Z, Ke Z, Xia Z, Hu Y (2010) Catalpol attenuates MPTP-induced neuronal degeneration of niagral striatal dopaminergic pathway in mice through elevating glial cell derived neurotropic factor in striatum. Neuroscience 167:174-184
65. Yang X, Mertens B, Lehtonen E, Vercammen L, Bockstael O, Chtarto A, Levivier M, Brotchi J, Michotte Y, Baekelandt V, Sarre S, Tenenbaum L (2009) Reversible neurochemical changes mediated by delayed intrastriatal glial cell line derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model. J Gene Med 11:899-912
66. Yasuda Y, Shimoda T, Uno K, Tateishi N, Furuya S, Yagi K (2008) The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains. J Neuroimmunol 204:43-51
67. Yurek DM, Fletcher-Turner A (2001) Differential expression of GDNF, BDNF, and NT-3 in the aging nigrostriatal system following a neurotoxic lesion. Brain Res 891:228-235